Avastin to treat metastatic colorectal cancer

Avastin (bevacizumab) is approved to treat metastatic colorectal cancer, or mCRC, for first- or second-line treatment in combination with intravenous fluorouracil–based chemotherapy. Avastin is also approved as a second-line treatment, when used with fluoropyrimidine-based (combined with irinotecan or oxaliplatin) chemotherapy, after cancer progresses following a first-line treatment that includes Avastin.

Keep in mind that Avastin is not approved for use after surgery was used as the primary treatment in patients with colon cancer which has not spread to other parts of the body.

Patients with recurrent glioblastoma (a form of brain cancer) who were treated with Avastin® (bevacizumab) alone experienced a slight survival advantage compared with patients treated with Avastin plus Camptosar® (irinotecan). These results were presented at the 2008 annual meeting of the American Society of Clinical Oncology.

How effective is Avastin for brain tumors?

The median overall survival was 7 months and the 9-month and 12-month overall survival was 28.1% and 20.6%, respectively. The objective response rate was 23.1%. The most common documented reason for bevacizumab discontinuation was disease progression (66.9%), followed by toxicity (6.9%).


There are no reviews yet.

Be the first to review “Avastin”

Your email address will not be published. Required fields are marked *

Shopping Cart